Swiss Pharmaceuticals & Biotech Big Green Snowflakes

Novartis

Market Cap: CHF 171.7b

Engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally.

Roche Holding

Market Cap: CHF 203.9b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.

Tecan Group

Market Cap: CHF 1.8b

Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.

Newron Pharmaceuticals

Market Cap: CHF 128.1m

A biopharmaceutical company, focus on the discovery and development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States.

Cosmo Pharmaceuticals

Market Cap: CHF 763.9m

Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.

SKAN Group

Market Cap: CHF 1.4b

Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally.

Santhera Pharmaceuticals Holding

Market Cap: CHF 184.9m

A specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia.

Bachem Holding

Market Cap: CHF 3.6b

Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.

Basilea Pharmaceutica

Market Cap: CHF 505.8m

Engages in the discovering, developing, and commercializing drugs for bacterial or fungal infections.

Siegfried Holding

Market Cap: CHF 3.9b

Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.

PolyPeptide Group

Market Cap: CHF 514.1m

Operates as a contract development and manufacturing company in Europe, the United States, and India.

Xlife Sciences

Market Cap: CHF 111.7m

Focuses on the development and commercialization of technologies in the life sciences sector.

Sandoz Group

Market Cap: CHF 14.2b

Develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide.

Relief Therapeutics Holding

Market Cap: CHF 31.2m

A biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally.

Galderma Group

Market Cap: CHF 18.6b

Operates as a dermatology company worldwide.

Molecular Partners

Market Cap: CHF 120.9m

A clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.

Lonza Group

Market Cap: CHF 38.3b

Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.

Addex Therapeutics

Market Cap: CHF 4.9m

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.

Idorsia

Market Cap: CHF 252.1m

A biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, and Canada.

Dottikon ES Holding

Market Cap: CHF 2.5b

Manufactures and sells performance chemicals, intermediates, and active pharmaceutical ingredients for the chemical, biotech, and pharmaceutical industries worldwide.

Kuros Biosciences

Market Cap: CHF 834.4m

Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.

Curatis Holding

Market Cap: CHF 49.9m

Engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases.

BioVersys

Market Cap: CHF 202.1m

A clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria.